{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:3369"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:3369","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"The effect of Adenovirus E1A on the human immunoproteasome and MHC complex","abstract":"Adenovirus E1A (AdE1A) is a viral oncoprotein that targets many cellular proteins and pathways, mainly those involved in transcriptional regulation. Proteasomes represent the major non-lysosomal mechanism responsible for protein degradation. Following interferon-γ treatment, three proteasome subunits are replaced by immunosubunits LMP2, LMP7 and MECL-1 producing immunoproteasomes. The proteasome and immunoproteasome generate peptide antigens for MHC class I presentation to cytotoxic T-cells. In this study, the effect of AdE1A on human immunoproteasomes as well as MHC class I and class II cell surface expression was examined. It was found that AdE1A interacts with the immunoproteasome subunit MECL-1 through its N-terminal and CR3 regions. AdE1A also down-regulated all three immunosubunit expressions during adenovirus infection, transformation and AdE1A transfection, with the exception of Ad5-transformed cells where immunosubunit expression remained unchanged. Furthermore, MHC class I expression remained unaffected in the same three backgrounds. However, in the Ad12 transformants MHC class I was generally reduced prior to IFNγ treatment but was expressed after. MHC class II surface expression, in contrast, was down-regulated in all cases, except in Ad5 infected cells. Similarly, AdE1A reduced IFNγ-stimulated STAT1 phosphorylation and transcriptional response to IFNγ. And finally, T-cell recognition of target cells was reduced in the presence of AdE1A. In conclusion, AdE1A targets the human immunoproteasome, both through direct binding and down-regulation of expression. It also targets the expression of MHC class I and class II surface expression.","abstract_html":"Adenovirus E1A (AdE1A) is a viral oncoprotein that targets many cellular proteins and pathways, mainly those involved in transcriptional regulation. Proteasomes represent the major non-lysosomal mechanism responsible for protein degradation. Following interferon-γ treatment, three proteasome subunits are replaced by immunosubunits LMP2, LMP7 and MECL-1 producing immunoproteasomes. The proteasome and immunoproteasome generate peptide antigens for MHC class I presentation to cytotoxic T-cells. In this study, the effect of AdE1A on human immunoproteasomes as well as MHC class I and class II cell surface expression was examined. It was found that AdE1A interacts with the immunoproteasome subunit MECL-1 through its N-terminal and CR3 regions. AdE1A also down-regulated all three immunosubunit expressions during adenovirus infection, transformation and AdE1A transfection, with the exception of Ad5-transformed cells where immunosubunit expression remained unchanged. Furthermore, MHC class I expression remained unaffected in the same three backgrounds. However, in the Ad12 transformants MHC class I was generally reduced prior to IFNγ treatment but was expressed after. MHC class II surface expression, in contrast, was down-regulated in all cases, except in Ad5 infected cells. Similarly, AdE1A reduced IFNγ-stimulated STAT1 phosphorylation and transcriptional response to IFNγ. And finally, T-cell recognition of target cells was reduced in the presence of AdE1A. In conclusion, AdE1A targets the human immunoproteasome, both through direct binding and down-regulation of expression. It also targets the expression of MHC class I and class II surface expression.","abstract_has_math":false,"creators":["Berhane, Sarah"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2012,"date_issued":"2012-07","date_published":"2012-07","updated_at":"2026-11-19T09:27:08Z","subjects":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/3369/1/Berhane_12_PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A3369","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Berhane, Sarah"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2012-07"]},{"key":"dc:date.issued","label":"Date","values":["2012-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Cancer Studies"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/3369/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/3369/1/Berhane_12_PhD.pdf","http://etheses.bham.ac.uk//id/eprint/3369/2/Decl_IS_Berhane_12_PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Adenovirus E1A (AdE1A) is a viral oncoprotein that targets many cellular proteins and pathways, mainly those involved in transcriptional regulation. Proteasomes represent the major non-lysosomal mechanism responsible for protein degradation. Following interferon-γ treatment, three proteasome subunits are replaced by immunosubunits LMP2, LMP7 and MECL-1 producing immunoproteasomes. The proteasome and immunoproteasome generate peptide antigens for MHC class I presentation to cytotoxic T-cells. In this study, the effect of AdE1A on human immunoproteasomes as well as MHC class I and class II cell surface expression was examined. It was found that AdE1A interacts with the immunoproteasome subunit MECL-1 through its N-terminal and CR3 regions. AdE1A also down-regulated all three immunosubunit expressions during adenovirus infection, transformation and AdE1A transfection, with the exception of Ad5-transformed cells where immunosubunit expression remained unchanged. Furthermore, MHC class I expression remained unaffected in the same three backgrounds. However, in the Ad12 transformants MHC class I was generally reduced prior to IFNγ treatment but was expressed after. MHC class II surface expression, in contrast, was down-regulated in all cases, except in Ad5 infected cells. Similarly, AdE1A reduced IFNγ-stimulated STAT1 phosphorylation and transcriptional response to IFNγ. And finally, T-cell recognition of target cells was reduced in the presence of AdE1A. In conclusion, AdE1A targets the human immunoproteasome, both through direct binding and down-regulation of expression. It also targets the expression of MHC class I and class II surface expression."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["The effect of Adenovirus E1A on the human immunoproteasome and MHC complex"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Berhane, Sarah"],"dc:date":["2012-07"],"dc:date.issued":["2012-07"],"dc:description.abstract":["Adenovirus E1A (AdE1A) is a viral oncoprotein that targets many cellular proteins and pathways, mainly those involved in transcriptional regulation. Proteasomes represent the major non-lysosomal mechanism responsible for protein degradation. Following interferon-γ treatment, three proteasome subunits are replaced by immunosubunits LMP2, LMP7 and MECL-1 producing immunoproteasomes. The proteasome and immunoproteasome generate peptide antigens for MHC class I presentation to cytotoxic T-cells. In this study, the effect of AdE1A on human immunoproteasomes as well as MHC class I and class II cell surface expression was examined. It was found that AdE1A interacts with the immunoproteasome subunit MECL-1 through its N-terminal and CR3 regions. AdE1A also down-regulated all three immunosubunit expressions during adenovirus infection, transformation and AdE1A transfection, with the exception of Ad5-transformed cells where immunosubunit expression remained unchanged. Furthermore, MHC class I expression remained unaffected in the same three backgrounds. However, in the Ad12 transformants MHC class I was generally reduced prior to IFNγ treatment but was expressed after. MHC class II surface expression, in contrast, was down-regulated in all cases, except in Ad5 infected cells. Similarly, AdE1A reduced IFNγ-stimulated STAT1 phosphorylation and transcriptional response to IFNγ. And finally, T-cell recognition of target cells was reduced in the presence of AdE1A. In conclusion, AdE1A targets the human immunoproteasome, both through direct binding and down-regulation of expression. It also targets the expression of MHC class I and class II surface expression."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/3369/1/Berhane_12_PhD.pdf","http://etheses.bham.ac.uk//id/eprint/3369/2/Decl_IS_Berhane_12_PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Cancer Studies"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/3369/"],"dc:subject":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public","staffonly"],"dc:title":["The effect of Adenovirus E1A on the human immunoproteasome and MHC complex"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:27:08Z"}